
Eight companies with immunotherapy approaches for brain tumors
May 22, 2012
MD Becker Partners' newsletter covering the life science industry

Our favorable outlook for the biotechnology industry remains intact for 2012 and is based on several key drivers

On March 25, 2011, Yervoy® [ipilimumab] by Bristol-Myers Squibb became the eleventh mAb approved by the FDA for the treatment of cancer.

Traditional wisdom holds that biotechnology companies benefit from collaborations with their larger pharmaceutical peers, which can help validate a company’s technology, provide capital to help fund clinical development, and enable access to experienced clinical, regulatory and commercial infrastructure. While this was certainly true in the early days of biotechnology, the industry has now matured – [...]
Keynote address "Creating the methodological framework for cancer immunotherapy success" from MD Becker Partners' 2nd Annual Cancer Immunotherapy: A Long-Awaited Reality Conference:
Life Science Digest is published by MD Becker Partners LLC, a boutique management and strategy consulting firm focusing on both public and private companies in the life science industry, including pharmaceuticals, biotechnology, and medical devices.
Interested in contributing articles to Life Science Digest? Send your request and a writing sample to: info@mdbpartners.com
Copyright © 2012 MD Becker Partners LLC · WordPress · Log in
Follow MD Becker Partners